Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.

[1]  J. Menon,et al.  Sideroblastic anemia. , 2020, Indian pediatrics.

[2]  K. Neugebauer.  Faculty Opinions recommendation of Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  A. Trumpp,et al.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.

[4]  M. Cazzola,et al.  Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts , 2016, British journal of haematology.

[5]  Mallory A. Havens,et al.  Splice-switching antisense oligonucleotides as therapeutic drugs , 2016, Nucleic acids research.

[6]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[7]  R. Kusec,et al.  Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes , 2016, Leukemia.

[8]  Michael R. Green,et al.  U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. , 2016, Molecular cell.

[9]  J. Boultwood,et al.  Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes. , 2016, Current pharmaceutical design.

[10]  O. Abdel-Wahab,et al.  Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis , 2016, Genes & development.

[11]  Saijuan Chen,et al.  Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes , 2016, Tumor Biology.

[12]  Arun K. Ghosh,et al.  Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages , 2016, RNA.

[13]  L. Shkreta,et al.  Defective control of pre–messenger RNA splicing in human disease , 2016, The Journal of cell biology.

[14]  G. Mufti,et al.  SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment , 2015, Nature Communications.

[15]  M. Cazzola,et al.  Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes , 2015 .

[16]  T. Haferlach,et al.  Categorizing Molecular Mutations in MDS and AML , 2015 .

[17]  J. Valcárcel,et al.  The pathogenicity of splicing defects: mechanistic insights into pre‐mRNA processing inform novel therapeutic approaches , 2015, EMBO reports.

[18]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[19]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[20]  Alexander V Penson,et al.  Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities , 2015, Proceedings of the National Academy of Sciences.

[21]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[22]  J. Boultwood,et al.  The molecular pathogenesis of the myelodysplastic syndromes , 2015, European journal of haematology.

[23]  L. Rassenti,et al.  Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B , 2015, Haematologica.

[24]  E. Campo,et al.  The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia , 2015, Oncotarget.

[25]  M. Calasanz,et al.  Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression , 2015, Leukemia.

[26]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[27]  Michael C. Ryan,et al.  Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. , 2015, Cancer cell.

[28]  R. Fulton,et al.  Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. , 2015, Cancer cell.

[29]  B. Ebert,et al.  Charting the "Splice" Routes to MDS. , 2015, Cancer cell.

[30]  S. Miyano,et al.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.

[31]  S. Jhanwar.  Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview. , 2015, Advances in biological regulation.

[32]  Dennis Carson,et al.  Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers , 2015, PLoS Comput. Biol..

[33]  P. Greenberg,et al.  MDS prognostic scoring systems – past, present, and future. , 2015, Best practice & research. Clinical haematology.

[34]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[35]  P. Campbell,et al.  Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.

[36]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[37]  Caterina Marchiò,et al.  SF3B1 mutations constitute a novel therapeutic target in breast cancer , 2014, The Journal of pathology.

[38]  Michelle C. Chen,et al.  Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated Erythropoiesis and a Stem Cell Disadvantage , 2014 .

[39]  M Cazzola,et al.  Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2014, Leukemia.

[40]  L. Ding,et al.  U2AF1 Mutations Alter Sequence Specificity of pre-mRNA Binding and Splicing , 2014, Leukemia.

[41]  P. Campbell,et al.  Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.

[42]  Philip Bradley,et al.  U2AF1 mutations alter splice site recognition in hematological malignancies , 2014, bioRxiv.

[43]  J. Barnard,et al.  Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron , 2014, Leukemia.

[44]  Marcel J T Reinders,et al.  Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. , 2014, Blood.

[45]  Hee-Jin Kim,et al.  Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts , 2014, Annals of Hematology.

[46]  S. Ogawa,et al.  Splicing factor mutations and cancer , 2014, Wiley interdisciplinary reviews. RNA.

[47]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[48]  A. Gregory Matera,et al.  A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.

[49]  G. Garcia-Manero.  CME Information: Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification and management , 2014 .

[50]  M. Cazzola,et al.  Refractory anemia with ring sideroblasts. , 2013, Best practice & research. Clinical haematology.

[51]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[52]  Seishi Ogawa,et al.  PRPF8 Defects Cause Missplicing in Myeloid Malignancies , 2014, Leukemia.

[53]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[54]  B. Ko,et al.  Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression , 2013, American journal of hematology.

[55]  C. Ghigna,et al.  Oncogenic Alternative Splicing Switches: Role in Cancer Progression and Prospects for Therapy , 2013, International journal of cell biology.

[56]  A. Polednak.  Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. , 2013, Cancer epidemiology.

[57]  David Gentien,et al.  SF3B1 mutations are associated with alternative splicing in uveal melanoma. , 2013, Cancer discovery.

[58]  H. Simon,et al.  Down-Regulation of Autophagy-Related Protein 5 (ATG5) Contributes to the Pathogenesis of Early-Stage Cutaneous Melanoma , 2013, Science Translational Medicine.

[59]  F. J. Ramos,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[60]  J. Maciejewski,et al.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.

[61]  G. Mufti,et al.  Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome , 2013, Haematologica.

[62]  D. Duelli,et al.  Targeting RNA splicing for disease therapy , 2013, Wiley interdisciplinary reviews. RNA.

[63]  M. Cazzola,et al.  The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts , 2013, Leukemia.

[64]  A. Burlingame,et al.  Rearrangements within human spliceosomes captured after exon ligation. , 2013, RNA.

[65]  E Mardis,et al.  Clonal diversity of recurrently mutated genes in myelodysplastic syndromes , 2013, Leukemia.

[66]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[67]  A. Jankowska,et al.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.

[68]  M. Frilander,et al.  The significant other: splicing by the minor spliceosome , 2012, Wiley interdisciplinary reviews. RNA.

[69]  Seishi Ogawa,et al.  Splicing factor mutations in myelodysplasia , 2012, International Journal of Hematology.

[70]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Aaron A Hoskins,et al.  The spliceosome: a flexible, reversible macromolecular machine. , 2012, Trends in biochemical sciences.

[72]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[73]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[74]  Claude Preudhomme,et al.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.

[75]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[76]  F. Allain,et al.  A syn–anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well , 2012, The EMBO journal.

[77]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[78]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[79]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[80]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[81]  Henning Urlaub,et al.  Semiquantitative Proteomic Analysis of the Human Spliceosome via a Novel Two-Dimensional Gel Electrophoresis Method , 2011, Molecular and Cellular Biology.

[82]  R. Kole,et al.  Modulation of RNA splicing as a potential treatment for cancer , 2011, Bioengineered bugs.

[83]  E. Soilleux,et al.  The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance , 2011, The Journal of experimental medicine.

[84]  R. Reed,et al.  The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. , 2011, Genes & development.

[85]  J. Valcárcel,et al.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.

[86]  Miaosheng Li,et al.  Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. , 2011, Chemistry.

[87]  S. Kojima,et al.  Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF , 2010, Cancer science.

[88]  Michael R. Green,et al.  The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. , 2010, Genes & development.

[89]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[90]  J. Manley,et al.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches , 2009, Nature Reviews Molecular Cell Biology.

[91]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[92]  Saverio Brogna,et al.  Nonsense-mediated mRNA decay (NMD) mechanisms , 2009, Nature Structural &Molecular Biology.

[93]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[94]  Luca Malcovati,et al.  The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts , 2008, PloS one.

[95]  Kinji Ohno,et al.  Human branch point consensus sequence is yUnAy , 2008, Nucleic acids research.

[96]  E. White,et al.  Autophagy suppresses tumor progression by limiting chromosomal instability. , 2007, Genes & development.

[97]  Xiang-Dong Fu,et al.  Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.

[98]  Brenda F Baker,et al.  Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.

[99]  Masaaki Komatsu,et al.  Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice , 2005, The Journal of cell biology.

[100]  J. Beggs,et al.  Prp8 protein: at the heart of the spliceosome. , 2005, RNA.

[101]  T. Yamori,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. , 2004, The Journal of antibiotics.

[102]  F. Muntoni,et al.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[103]  M. Cazzola,et al.  Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. , 2003, Blood.

[104]  Barbara Hoffman,et al.  The proto-oncogene c-myc in hematopoietic development and leukemogenesis , 2002, Oncogene.

[105]  Michael Q. Zhang,et al.  Exonic Splicing Enhancer Motif Recognized by Human SC35 under Splicing Conditions , 2000, Molecular and Cellular Biology.

[106]  Michael R. Green,et al.  Functional recognition of the 3′ splice site AG by the splicing factor U2AF35 , 1999, Nature.

[107]  W. Johnson,et al.  Diffusion mechanisms in metallic supercooled liquids and glasses , 1999, Nature.

[108]  T. Maniatis,et al.  Multiple Distinct Splicing Enhancers in the Protein-Coding Sequences of a Constitutively Spliced Pre-mRNA , 1999, Molecular and Cellular Biology.

[109]  Or Gozani,et al.  A Potential Role for U2AF-SAP 155 Interactions in Recruiting U2 snRNP to the Branch Site , 1998, Molecular and Cellular Biology.

[110]  T. Maniatis,et al.  Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. , 1998, Molecular cell.

[111]  Xiang-Dong Fu,et al.  A protein related to splicing factor U2AF35 that interacts with U2AF65 and SR proteins in splicing of pre-mRNA , 1997, Nature.

[112]  H. Nakajima,et al.  New Antitumor Substances, FR901463, FR901464, and FR901465. Part 3. Structures of FR901463, FR901464, and FR901465. , 1997 .

[113]  H. Tanaka,et al.  New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465. , 1997, The Journal of antibiotics.

[114]  M. Okuhara,et al.  New Antitumor Substances, FR901463, FR901464 and FR901465 , 1996 .

[115]  Michael R. Green,et al.  A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly , 1988, Cell.

[116]  L. Swart.  Patients with lower-risk myelodysplastic syndromes: in scope of iron related complications , 2019 .

[117]  A. Subtil.  Myeloid Neoplasms. , 2017, Clinics in laboratory medicine.

[118]  R. Bejar.  Splicing Factor Mutations in Cancer. , 2016, Advances in experimental medicine and biology.

[119]  J. Boultwood,et al.  Application of genome editing technologies to the study and treatment of hematological disease. , 2016, Advances in biological regulation.

[120]  M. Cazzola,et al.  Disruption of SF 3 B 1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2015 .

[121]  David P Steensma,et al.  Myelodysplastic Syndromes: Diagnosis and Treatment. , 2015, Mayo Clinic proceedings.

[122]  J. Boultwood,et al.  The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. , 2014, Advances in biological regulation.

[123]  P. LoRusso,et al.  A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors , 2013, Investigational New Drugs.

[124]  P. Potter,et al.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. , 2013, Drug discovery today.

[125]  E. Soilleux,et al.  The autophagy protein Atg 7 is essential for hematopoietic stem cell maintenance , 2011 .

[126]  A. MacMillan,et al.  Structural model of the p14/SF3b155 · branch duplex complex. , 2011, RNA.

[127]  J. Bennett,et al.  The myelodysplastic syndromes: diagnosis and treatment. , 2006, Mayo Clinic proceedings.